<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="iso-abbrev">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="publisher-id">nar</journal-id>
    <journal-title-group>
      <journal-title>Nucleic Acids Research</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">0305-1048</issn>
    <issn pub-type="epub">1362-4962</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">8728189</article-id>
    <article-id pub-id-type="pmid">34669962</article-id>
    <article-id pub-id-type="doi">10.1093/nar/gkab962</article-id>
    <article-id pub-id-type="publisher-id">gkab962</article-id>
    <article-categories>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI00010</subject>
      </subj-group>
      <subj-group subj-group-type="heading">
        <subject>Database Issue</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>UbiBrowser 2.0: a comprehensive resource for proteome-wide known and predicted ubiquitin ligase/deubiquitinase–substrate interactions in eukaryotic species</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4559-5450</contrib-id>
        <name>
          <surname>Wang</surname>
          <given-names>Xun</given-names>
        </name>
        <aff><institution>State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics</institution>, Beijing 102206, <country country="CN">China</country></aff>
        <xref rid="FN1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2009-7079</contrib-id>
        <name>
          <surname>Li</surname>
          <given-names>Yang</given-names>
        </name>
        <aff><institution>State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics</institution>, Beijing 102206, <country country="CN">China</country></aff>
        <xref rid="FN1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>He</surname>
          <given-names>Mengqi</given-names>
        </name>
        <aff><institution>State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics</institution>, Beijing 102206, <country country="CN">China</country></aff>
        <xref rid="FN1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Kong</surname>
          <given-names>Xiangren</given-names>
        </name>
        <aff><institution>College of Life Sciences, Hebei University</institution>, Baoding 071002, <country country="CN">China</country></aff>
        <xref rid="FN1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Jiang</surname>
          <given-names>Peng</given-names>
        </name>
        <aff><institution>School of Basic Medical Sciences, Anhui Medical University</institution>, Hefei 230032, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Liu</surname>
          <given-names>Xi</given-names>
        </name>
        <aff><institution>College of Life Sciences, Hebei University</institution>, Baoding 071002, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Diao</surname>
          <given-names>Lihong</given-names>
        </name>
        <aff><institution>State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics</institution>, Beijing 102206, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhang</surname>
          <given-names>Xinlei</given-names>
        </name>
        <aff><institution>Beijing Geneworks Technology Co.,Ltd.</institution>, Beijing 100101, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Li</surname>
          <given-names>Honglei</given-names>
        </name>
        <aff><institution>Beijing Geneworks Technology Co.,Ltd.</institution>, Beijing 100101, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Ling</surname>
          <given-names>Xinping</given-names>
        </name>
        <aff><institution>College of Life Sciences, Hebei University</institution>, Baoding 071002, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Xia</surname>
          <given-names>Simin</given-names>
        </name>
        <aff><institution>School of Basic Medical Sciences, Anhui Medical University</institution>, Hefei 230032, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Liu</surname>
          <given-names>Zhongyang</given-names>
        </name>
        <aff><institution>State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics</institution>, Beijing 102206, <country country="CN">China</country></aff>
        <aff><institution>College of Life Sciences, Hebei University</institution>, Baoding 071002, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2866-4904</contrib-id>
        <name>
          <surname>Liu</surname>
          <given-names>Yuan</given-names>
        </name>
        <aff><institution>State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics</institution>, Beijing 102206, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Cui</surname>
          <given-names>Chun-Ping</given-names>
        </name>
        <aff><institution>State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics</institution>, Beijing 102206, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Wang</surname>
          <given-names>Yan</given-names>
        </name>
        <aff><institution>State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics</institution>, Beijing 102206, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Tang</surname>
          <given-names>Liujun</given-names>
        </name>
        <aff><institution>State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics</institution>, Beijing 102206, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhang</surname>
          <given-names>Lingqiang</given-names>
        </name>
        <!--zhanglq@nic.bmi.ac.cn-->
        <aff><institution>State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics</institution>, Beijing 102206, <country country="CN">China</country></aff>
        <aff><institution>School of Basic Medical Sciences, Anhui Medical University</institution>, Hefei 230032, <country country="CN">China</country></aff>
        <xref rid="COR3" ref-type="corresp"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>He</surname>
          <given-names>Fuchu</given-names>
        </name>
        <!--hefc@nic.bmi.ac.cn-->
        <aff><institution>State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics</institution>, Beijing 102206, <country country="CN">China</country></aff>
        <xref rid="COR2" ref-type="corresp"/>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8680-0468</contrib-id>
        <name>
          <surname>Li</surname>
          <given-names>Dong</given-names>
        </name>
        <!--lidong.bprc@foxmail.com-->
        <aff><institution>State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics</institution>, Beijing 102206, <country country="CN">China</country></aff>
        <aff><institution>College of Life Sciences, Hebei University</institution>, Baoding 071002, <country country="CN">China</country></aff>
        <aff><institution>School of Basic Medical Sciences, Anhui Medical University</institution>, Hefei 230032, <country country="CN">China</country></aff>
        <xref rid="COR1" ref-type="corresp"/>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="COR1">To whom correspondence should be addressed. Tel: +86 1061777057; Fax: +86 1061777004; Email: <email>lidong.bprc@foxmail.com</email></corresp>
      <corresp id="COR2">Correspondence may also be addressed to Fuchu He. Tel: +86 1061771001; Fax: +86 1061777004; Email: <email>hefc@nic.bmi.ac.cn</email></corresp>
      <corresp id="COR3">Correspondence may also be addressed to Lingqiang Zhang. Tel: +86 1061777009; Fax: +86 1061777089; Email: <email>zhanglq@nic.bmi.ac.cn</email></corresp>
      <fn id="FN1">
        <p>The authors wish it to be known that, in their opinion, the first four authors should be regarded as joint First Authors.</p>
      </fn>
    </author-notes>
    <pub-date pub-type="collection">
      <day>07</day>
      <month>1</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2021-10-20">
      <day>20</day>
      <month>10</month>
      <year>2021</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>20</day>
      <month>10</month>
      <year>2021</year>
    </pub-date>
    <volume>50</volume>
    <issue>D1</issue>
    <fpage>D719</fpage>
    <lpage>D728</lpage>
    <history>
      <date date-type="accepted">
        <day>04</day>
        <month>10</month>
        <year>2021</year>
      </date>
      <date date-type="rev-recd">
        <day>30</day>
        <month>9</month>
        <year>2021</year>
      </date>
      <date date-type="received">
        <day>15</day>
        <month>9</month>
        <year>2021</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2021. Published by Oxford University Press on behalf of Nucleic Acids Research.</copyright-statement>
      <copyright-year>2022</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact <email>journals.permissions@oup.com</email></license-p>
      </license>
    </permissions>
    <self-uri xlink:href="gkab962.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p>As an important post-translational modification, ubiquitination mediates ∼80% of protein degradation in eukaryotes. The degree of protein ubiquitination is tightly determined by the delicate balance between specific ubiquitin ligase (E3)-mediated ubiquitination and deubiquitinase-mediated deubiquitination. In 2017, we developed UbiBrowser 1.0, which is an integrated database for predicted human proteome-wide E3–substrate interactions. Here, to meet the urgent requirement of proteome-wide E3/deubiquitinase–substrate interactions (ESIs/DSIs) in multiple organisms, we updated UbiBrowser to version 2.0 (<ext-link xlink:href="http://ubibrowser.ncpsb.org.cn" ext-link-type="uri">http://ubibrowser.ncpsb.org.cn</ext-link>). Using an improved protocol, we collected 4068/967 known ESIs/DSIs by manual curation, and we predicted about 2.2 million highly confident ESIs/DSIs in 39 organisms, with &gt;210-fold increase in total data volume. In addition, we made several new features in the updated version: (i) it allows exploring proteins’ upstream E3 ligases and deubiquitinases simultaneously; (ii) it has significantly increased species coverage; (iii) it presents a uniform confidence scoring system to rank predicted ESIs/DSIs. To facilitate the usage of UbiBrowser 2.0, we also redesigned the web interface for exploring these known and predicted ESIs/DSIs, and added functions of ‘Browse’, ‘Download’ and ‘Application Programming Interface’. We believe that UbiBrowser 2.0, as a discovery tool, will contribute to the study of protein ubiquitination and the development of drug targets for complex diseases.</p>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Natural Science Foundation of China</institution>
            <institution-id institution-id-type="DOI">10.13039/501100001809</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>32088101</award-id>
        <award-id>31871341</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Key Research and Development Program of China</institution>
            <institution-id institution-id-type="DOI">10.13039/501100012166</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>2020YFE0202200</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Beijing Talents Foundation</institution>
            <institution-id institution-id-type="DOI">10.13039/501100017616</institution-id>
          </institution-wrap>
        </funding-source>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="10"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="SEC1">
    <title>INTRODUCTION</title>
    <p>Protein ubiquitination is a vital post-translational modification in eukaryotes, which regulates a plethora of intracellular processes, including endogenous protein stability, enzyme activity, DNA damage response, and signal transduction (<xref rid="B1" ref-type="bibr">1</xref>). Like most protein post-translational modifications, ubiquitination is a reversible dynamic process. Ubiquitin, a ubiquitously expressed and highly conserved 76-amino acid protein in eukaryotes, can be covalently conjugated to a substrate protein by tight regulation of ubiquitin activating enzyme (E1)-ubiquitin conjugating enzyme (E2)-ubiquitin ligase (E3) cascade and removed from the substrate by deubiquitinase (DUB). The degree of protein ubiquitination is tightly determined by the balance between specific E3-mediated ubiquitination and DUB-mediated deubiquitination (<xref rid="B2" ref-type="bibr">2</xref>). Dysregulation of the dynamic ubiquitination process may induce multiple diseases, such as Parkinson's disease (<xref rid="B3" ref-type="bibr">3</xref>) and Alzheimer's disease (<xref rid="B4" ref-type="bibr">4</xref>). Especially, in recent years, E3s/DUBs have been found to be implicated in tumorigenesis at multiple levels (<xref rid="B5" ref-type="bibr">5</xref>). Identification of interactions between E3/DUB and substrate has provided novel insights into cancer therapy. For example, the drug of Mitoxantrone (a USP11 inhibitor) has been approved by FDA to treat the hormone-refractory prostate cancer (<xref rid="B6" ref-type="bibr">6</xref>).</p>
    <p>Several experimental methods have been developed for identifying interactions between E3/DUB and substrates, such as protein microarrays (<xref rid="B7" ref-type="bibr">7</xref>), GPS profiling (<xref rid="B8" ref-type="bibr">8</xref>), mass spectrometry (<xref rid="B9" ref-type="bibr">9</xref>), live phage display library (<xref rid="B10" ref-type="bibr">10</xref>) and so on. However, due to the E3/DUB substrates’ low expression levels and their intrinsically weak interactions with enzyme, these methods are often laborious, expensive and low efficient. Therefore, it is an urgent need to identify proteome-wide E3/DUB-substrate interactions by bioinformatics strategy. In 2017, we presented UbiBrowser 1.0 (<xref rid="B11" ref-type="bibr">11</xref>), the first bioinformatics database for predicted proteome-wide E3–substrate interactions (ESIs) in human. Since the publication of UbiBrowser, it has received widespread attention (<xref rid="B12" ref-type="bibr">12</xref>,<xref rid="B13" ref-type="bibr">13</xref>). UbiBrowser has been visited 100 000+ times, making great advancements to the field. Moreover, we have received lots of feedback asking whether we can add the dataset of deubiquitinase–substrate interaction (DSI), and the dataset of ESIs in non-human species. Based on the statistics of 17 800 ubiquitination-related papers in PubMed (2019–2021), we found that ∼37% of these papers were about DSIs, and ∼55% of the ESIs/DSIs were identified in non-human species. Consequently, it is urgent to identify the proteome-wide ESIs/DSIs in multiple species. In fact, many efforts have been devoted to identifying more ESIs/DSIs in multiple organisms. hUbiquitome is the pioneer database for experimentally verified ubiquitination cascades in humans, which contains 344/14 known human ESIs/DSIs (<xref rid="B14" ref-type="bibr">14</xref>). Subsequently, Chen <italic toggle="yes">et al.</italic> manually collected 1806/389 known human ESIs/DSIs from literature (<xref rid="B15" ref-type="bibr">15</xref>), and they also predicted 500 high confidence DSIs for 54 human USPs (Ubiquitin-specific-processing proteases) (<xref rid="B16" ref-type="bibr">16</xref>). Li <italic toggle="yes">et al.</italic> developed the database of UbiNet (<xref rid="B17" ref-type="bibr">17</xref>), holding 3332 experimentally verified ESIs in 20 eukaryotes. All these efforts present precious E3/DUB-substrate interaction datasets for the field of ubiquitination, however, there is still no database for comprehensively providing proteome-wide known and predicted E3/DUB-substrate interactions in multiple species.</p>
    <p>To fill this gap, we updated UbiBrowser to version 2.0, a comprehensive resource for proteome-wide known and predicted ESIs/DSIs in multiple eukaryotic species. Compared with UbiBrowser 1.0, major improvements in UbiBrowser 2.0 include: 4068 known ESIs and 967 known DSIs, proteome-wide predicted DSIs, and significantly increased species coverage (Figure <xref rid="F1" ref-type="fig">1</xref>). We manually curated known ESIs/DSIs from PubMed abstracts, predicted the proteome-wide human DSIs based on the naïve Bayesian classifier protocol that we built before (<xref rid="B11" ref-type="bibr">11</xref>), and inferred proteome-wide ESIs/DSIs in 38 non-human species by homology mapping (Figure <xref rid="F1" ref-type="fig">1</xref>). To facilitate the usage of the added ESI/DSI datasets, we redesigned the web interface and added functions of ‘Browse’, ‘Download’ and ‘API’.</p>
    <fig position="float" id="F1">
      <label>Figure 1.</label>
      <caption>
        <p>Overview of UbiBrowser 2.0, a comprehensive resource for proteome-wide known and predicted ESIs/DSIs in eukaryotic species. First, known ESIs/DSIs were manually curated from literature. Then, proteome-wide ESIs/DSIs in human were predicted by our published protocol for UbiBrowser 1.0 (<xref rid="B11" ref-type="bibr">11</xref>). The ‘interolog’-based approach was employed to transfer ESIs/DSIs from human to 38 non-human species (<xref rid="B24" ref-type="bibr">24</xref>). ESI: E3–substrate interaction; DSI: deubiquitinase–substrate interaction; API: application programming interface; ‘interolog’: a conserved interaction between a pair of proteins which are interacting orthologs in another species.</p>
      </caption>
      <graphic xlink:href="gkab962fig1" position="float"/>
    </fig>
  </sec>
  <sec id="SEC2">
    <title>DATA STATISTICS</title>
    <p>UbiBrowser 2.0 comprises 4068 known ESIs in 38 species, and 967 known DSIs in eight species (Figure <xref rid="F2" ref-type="fig">2A</xref>), which is the biggest database of known ESIs/DSIs. The distribution of known E3/DUB-substrate interactions across species is presented in Figure <xref rid="F2" ref-type="fig">2B</xref>. UbiBrowser 2.0 also predicted high confidence ESIs/DSIs in 39 species (Figure <xref rid="F2" ref-type="fig">2C</xref>). The number of predicted high confidence ESIs/DSIs significantly increased from 14 419/0 to 1 884 676/303 214, compared with that in UbiBrowser 1.0. As illustrated in Figure <xref rid="F2" ref-type="fig">2D</xref>, E3s and DUBs, involved in the high confidence predicted ESIs and DSIs, are of high coverage against all genome-encoded E3s and DUBs in most of 39 organisms. The main E3/DUB types (RING, DWD, SINGLE_Other, F-box, SOCS/VHL/BC-box, BTB_3, HECT, BTB_Other, UBOX, CDC20 for E3; USP, JAMM, OTU, ULP, UCH, MINDY, Josephin for DUB) (<xref rid="B18" ref-type="bibr">18</xref>) are covered by UbiBrowser 2.0 predicted ESIs/DSIs in all 39 species (Figure <xref rid="F2" ref-type="fig">2E</xref>). The predicted E3/DUB substrates of eight well-studied species share the similar functional distribution against the main Gene Ontology (<xref rid="B19" ref-type="bibr">19</xref>) categories (metabolic process, response to stimulus, signal transduction, regulation of molecular function, cell cycle process and cell growth) (Figure <xref rid="F2" ref-type="fig">2F</xref>). The above data statistics suggest that the predicted ESI/DSI datasets of UbiBrowser 2.0 are of no distinct bias.</p>
    <fig position="float" id="F2">
      <label>Figure 2.</label>
      <caption>
        <p>Data statistics of UbiBrowser 2.0. (<bold>A</bold>) Known ESIs/DSIs comparison between UbiBrowser 2.0 and other databases. (<bold>B</bold>) Number of known ESIs/DSIs across multiple organisms. (<bold>C</bold>) Number of high confidence predicted ESIs/DSIs in 39 organisms. (<bold>D</bold>) Coverage of E3s/DUBs in high confidence predicted ESIs/DSIs against all genome-encoded E3s/DUBs across 39 organisms. (<bold>E</bold>) Family distribution (<xref rid="B18" ref-type="bibr">18</xref>) of E3s/DUBs in high confidence predicted ESIs/DSIs across 39 organisms. From outside to inside, circles corresponding to 39 organisms in alphabetical order. (<bold>F</bold>) Gene Ontology biological process (<xref rid="B19" ref-type="bibr">19</xref>) analysis for high confidence substrates predicted by E3s/DUBs across <italic toggle="yes">D. melanogaster, D. rerio, G. gallus, P. troglodytes, S. scrofa, S. cerevisiae, M. musculus</italic> and <italic toggle="yes">H. sapiens</italic> (from outside to inside).</p>
      </caption>
      <graphic xlink:href="gkab962fig2" position="float"/>
    </fig>
  </sec>
  <sec id="SEC3">
    <title>EXPANDED DATABASE CONTENT</title>
    <sec id="SEC3-1">
      <title>Manual curation for known E3/DUB-substrate interactions</title>
      <p>To collect known ESIs/DSIs, we downloaded all PubMed abstracts from 1982 to 2021, and retained those candidate abstracts containing the following keyword combinations: (‘ubiquitin ligase’ OR ‘ubiquitin ligases’ OR ‘E3 ligase’ OR ‘E3 ligases’ OR ‘deubiquitinase’ OR ‘deubiquitinases’ OR ‘deubiquitinating enzyme’ OR ‘deubiquitinating enzymes’ OR ‘DUB’) AND (‘substrate’ OR ‘substrates’). Next, all candidate abstracts were manually checked to extract known ESIs/DSIs by three experienced researchers independently. Then, these selected candidate ESIs/DSIs and the supporting sentences were manually reviewed by our curation team consisting of three experts. The curation team also integrated known ESIs/DSIs in the published ubiquitination datasets (<xref rid="B14" ref-type="bibr">14–17</xref>). Finally, 5035 experimentally validated ESIs/DSIs (4068 ESIs in 38 species and 967 DSIs in 8 species) were deposited in UbiBrowser 2.0 (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S1</xref>).</p>
    </sec>
    <sec id="SEC3-2">
      <title>Prediction of human proteome-wide E3/Deubiquitinase-substrate interaction dataset</title>
      <p>The ubiquitination status of a protein is determined by a delicate balance between two opposing forces: ubiquitination mediated by E3 ubiquitin ligases and deubiquitination mediated by DUBs (<xref rid="B2" ref-type="bibr">2</xref>). In UbiBrowser 1.0, a naïve Bayesian classifier was used to predict the human ubiquitin ligase-substrate interactions (<xref rid="B11" ref-type="bibr">11</xref>). UbiBrowser 2.0 inherited the ESI prediction protocol from version 1.0 (<xref rid="B11" ref-type="bibr">11</xref>). To verify the reliability, we have implemented the 5-fold cross-validation, independent dataset validation and also the experimental validation in our previous publication of UbiBrowser 1.0 (<xref rid="B11" ref-type="bibr">11</xref>). Some of these predicted human ESIs by UbiBrowser 1.0 have been further experimentally validated by independent studies (<xref rid="B12" ref-type="bibr">12</xref>,<xref rid="B13" ref-type="bibr">13</xref>). Considering that the identification of DUB-substrate interactions is of equal significance for maintaining ubiquitin homeostasis (<xref rid="B2" ref-type="bibr">2</xref>), we took the same protocol as version1.0 (<xref rid="B11" ref-type="bibr">11</xref>) to predict the human DUB-substrate interactions (Supplementary Methods). Four heterogeneous biological evidences were integrated to construct the Bayesian model (<xref rid="B11" ref-type="bibr">11</xref>), including Gene Ontology (GO) (<xref rid="B19" ref-type="bibr">19</xref>) term pair, domain pair, DUB recognition consensus motif (<xref rid="B20" ref-type="bibr">20</xref>) and protein interaction network loop (<xref rid="B21" ref-type="bibr">21</xref>) (Figure <xref rid="F3" ref-type="fig">3A</xref>, <xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S1</xref>). Both 5-fold cross-validation and independent test were adopted to evaluate the performance of DSI prediction (<xref rid="B11" ref-type="bibr">11</xref>). A golden standard positive data set with 495 DSIs by manually curating PubMed before January 2018 was used for five-fold cross-validation, while a data set with 66 DSIs after January 2018 for independent test. We plotted ROC curves (<xref rid="B22" ref-type="bibr">22</xref>) in Figure <xref rid="F3" ref-type="fig">3B</xref> and <xref rid="F3" ref-type="fig">C</xref> by computing the true positive rate and false positive rate against different likelihood ratio (<italic toggle="yes">LR</italic>) cutoff during cross-validation test and independent test. We found that this Bayesian model has the ROC curve area of 0.85 against the five-fold cross-validation (Figure <xref rid="F3" ref-type="fig">3B</xref>), and the area of 0.71 against the independent test set (Figure <xref rid="F3" ref-type="fig">3C</xref>), which suggest that our model (<xref rid="B11" ref-type="bibr">11</xref>) is of certain prediction power for new DSIs.</p>
      <fig position="float" id="F3">
        <label>Figure 3.</label>
        <caption>
          <p>Derivation of human proteome-wide predicted deubiquitinase–substrate interaction. (<bold>A</bold>) Protocol of naïve Bayesian classifier to predict human deubiquitinase–substrate interaction (DSI) prediction (<xref rid="B11" ref-type="bibr">11</xref>). Based on the golden standard dataset (GSD) constructed by manual curation, four supporting biological evidences were identified and their reliability was assessed by likelihood ratio. For each potential DSI, the likelihood ratio from individual evidence will be integrated into a composite likelihood ratio (<italic toggle="yes">LR</italic><sub>comp</sub>) and transformed into a final confidence score. (<bold>B</bold>, <bold>C</bold>) Performance of the model evaluated by five-fold cross-validation and independent test set validation. Each point on ROC curves of assessment models corresponds to sensitivity and specificity against a particular likelihood ratio cutoff. <italic toggle="yes">TPR</italic> (true positive rate, sensitivity) and <italic toggle="yes">FPR</italic> (false positive rate, 1 – specificity) were computed during two assessment procedures: the five-fold cross-validation (B) and independent test set validation (C).</p>
        </caption>
        <graphic xlink:href="gkab962fig3" position="float"/>
      </fig>
    </sec>
    <sec id="SEC3-3">
      <title>Transferring E3/DUB-substrate interactions from human to 38 non-human species</title>
      <p>The ubiquitin signaling system was supposed to be of certain conservation (<xref rid="B23" ref-type="bibr">23</xref>). Therefore, we adopted the well-recognized ‘interolog’-based strategy (<xref rid="B24" ref-type="bibr">24</xref>) to transfer both the known and predicted E3/DUB-substate interactions with high confidence from human to 38 non-human species. First, we obtained the ortholog information between human and non-human species (such as <italic toggle="yes">Mus musculus, Rattus norvegicus</italic> and <italic toggle="yes">Drosophila melanogaster</italic>) from the InParanoid database (Released version 8.0) (<xref rid="B25" ref-type="bibr">25</xref>). Each human protein was mapped to a non-human protein with the highest orthology score. Then, the interactions between human E3s/DUBs and substrates were transferred to orthologous protein pairs in the non-human species (Figure <xref rid="F4" ref-type="fig">4A</xref>).</p>
      <fig position="float" id="F4">
        <label>Figure 4.</label>
        <caption>
          <p>Transferring of ubiquitin ligase/deubiquitinase–substrate interactions from human to non-human species. (<bold>A</bold>) Homologous mapping and confidence scoring scheme (please refer to text for details). (<bold>B</bold>) Number of overlapping interactions between the predicted and manually curated interactions in non-human species (observed overlapping links versus random expectation). The <italic toggle="yes">p</italic> value was obtained by the binomial test (one-sided). ESI: E3–substrate interaction; DSI: deubiquitinase–substrate interaction.</p>
        </caption>
        <graphic xlink:href="gkab962fig4" position="float"/>
      </fig>
      <p>After the homology mapping, we took the similar protocol as UbiBrowser 1.0 (<xref rid="B11" ref-type="bibr">11</xref>) to compute the derived non-human E3/DUB-substrate interactions’ confidence score based on four supporting biological evidences, including domain pair, Gene Ontology term pair, DUB recognition consensus motif and protein interaction network loop (Figure <xref rid="F4" ref-type="fig">4A</xref>). Based on the protein domain data from Pfam (<xref rid="B26" ref-type="bibr">26</xref>) (released version 33.1), the supporting evidence of domain pairs in human was transferred to 38 non-human species. The <italic toggle="yes">LR</italic>s of these domain pairs were recalculated based on the protein domain distribution of target species (<xref rid="B11" ref-type="bibr">11</xref>). The <italic toggle="yes">LR</italic> calculation of Gene Ontology term pair feature followed the similar protocol as that of domain pair (<xref rid="B11" ref-type="bibr">11</xref>). The supporting evidence of human E3/DUB recognition sequence motif of substrates was directly mapped to 38 non-human species after checking whether the motif was matched in the substrate protein sequence of target species (<xref rid="B11" ref-type="bibr">11</xref>). As for the supporting evidence of network topology, human protein interaction network (<xref rid="B21" ref-type="bibr">21</xref>) was firstly transferred to non-human species by the ‘interolog’-based strategy (<xref rid="B24" ref-type="bibr">24</xref>), generating high confidence orthologous protein–protein interaction networks (PPIN) for 38 non-human species, and then for each derived ESI/DSI, the number of involved four-interaction loops in the corresponding PPIN was counted for the <italic toggle="yes">LR</italic>. Ultimately, <italic toggle="yes">LR</italic>s from four biological evidences will be multiplied and transformed into the confidence score (<xref rid="B11" ref-type="bibr">11</xref>) for target ESI/DSI (Supplementary Methods, <xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S1</xref>).</p>
      <p>Finally, we obtained 1.77/0.28 million high confidence predicted ESIs/DSIs in 38 non-human species based on the above protocol. By manual curation on PubMed, we also obtained 560, 71 and 47 ESIs in <italic toggle="yes">M. musculu</italic>s, <italic toggle="yes">R. norvegicus</italic> and <italic toggle="yes">D. melanogaster</italic>, and collected 79 DSIs in <italic toggle="yes">M. musculus</italic>. Interestingly, we found that the number of the overlapping interactions between our predicted ESIs/DSIs and the manual curated ESIs/DSIs is significantly higher than random expectation (Figure <xref rid="F4" ref-type="fig">4B</xref>), suggesting that our improved identification strategy for ESIs/DSIs in non-human species is of certain reliability.</p>
    </sec>
  </sec>
  <sec id="SEC4">
    <title>ENHANCED USER INTERFACE</title>
    <p>To facilitate the usage of newly added known and predicted E3/DUB-substrate interaction datasets in multiple organisms by the community, we re-designed the web interface and added new functionalities of ‘Browse’, ‘Download’ and ‘API’, which promote navigation and usability (Figure <xref rid="F5" ref-type="fig">5</xref>).</p>
    <fig position="float" id="F5">
      <label>Figure 5.</label>
      <caption>
        <p>A screenshot of the redesigned UbiBrowser 2.0 interface. (<bold>A</bold>) Three ‘Search’ pages with the added options for ‘process’ and ‘species’. Users can specify the prediction process as ‘Ubiquitination’ or ‘Deubiquitination’, and designate whether the query protein is ‘Ubiquitin ligase (E3)’, ‘Deubiquitinase (DUB)’ or ‘Substrate’. The current version of UbiBrowser supports queries in 39 organisms. (<bold>B</bold>) ‘Browse’ page for known (left panel) and predicted (right panel) E3/DUB-substrate interactions across 39 organisms. (<bold>C</bold>) Network view for the retrieved known and predicted ESIs/DSIs. Red node: known interactor; blue node: predicted interactor. (<bold>D</bold>) Network view for the retrieved predicted ESIs/DSIs (confidence mode). Node size and edge width are positively proportional to the confidence score. The inset is the evidence mode, where various coloured edges between the central node and the surrounding nodes represent different types of supporting evidence. (<bold>E</bold>) Supporting literature information page for the known ESIs/DSIs, with the entries of E3/DUB and substrate in abstract texts are highlighted in colour. (<bold>F</bold>) Supporting evidence page for the predicted ESIs/DSIs. Clicking on each red node for known interactor in the network view (C) will pop up the corresponding supporting literature information (E); meanwhile, the blue nodes for predicted interactors in the network view (C and D) can lead to the supporting evidences page (F). ESI: E3–substrate interaction; DSI: deubiquitinase–substrate interaction.</p>
      </caption>
      <graphic xlink:href="gkab962fig5" position="float"/>
    </fig>
    <sec id="SEC4-1">
      <title>Search</title>
      <p>Options of ‘process’ and ‘species’ have been added to the improved search box (Figure <xref rid="F5" ref-type="fig">5A</xref>). Users can specify the prediction process as ‘Ubiquitination’ or ‘Deubiquitination’, and designate whether the query protein is ‘Ubiquitin ligase (E3)’, ‘Deubiquitinase (DUB)’ or ‘Substrate’. The current version of UbiBrowser supports the searching of ESIs/DSIs in 39 organisms. After the searching by ‘Protein Name’, ‘Database ID’ or ‘Protein Sequence’, the enhanced network view will be presented for known and predicted interactions (Figure <xref rid="F5" ref-type="fig">5C</xref>).</p>
    </sec>
    <sec id="SEC4-2">
      <title>Browse</title>
      <p>In order to help users intuitively view proteome-wide known and predicted E3/DUB-substrate interactions in 39 organisms, the ‘Browse’ function was added in UbiBrowser 2.0 (Figure <xref rid="F5" ref-type="fig">5B</xref>) (<xref rid="B11" ref-type="bibr">11</xref>). On the ‘Browse’ page, the taxonomy tree provides attribute hierarchy that can be applied to show the distribution of the interactions with regard to several specific properties (e.g. species, interaction type, E3/DUB family classification), and to allow users to browse a subset of these proteome-wide datasets in a selected attribution for the hierarchy (Figure <xref rid="F5" ref-type="fig">5B</xref>). The report panel provides further details about the known/predicted interaction entries, including supporting literature information for known interactions and calculated scores for predicted interactions. The report panel also presents internal links to detailed information page (Figure <xref rid="F5" ref-type="fig">5E</xref> and <xref rid="F5" ref-type="fig">F</xref>).</p>
    </sec>
    <sec id="SEC4-3">
      <title>Network view for retrieved results</title>
      <p>A network view was designed to visualize the retrieved known and predicted ESIs/DSIs, with the central node is the query E3/DUB or substrate, and the surrounding nodes are the retrieved substrates or E3s/DUBs (Figure <xref rid="F5" ref-type="fig">5C</xref> and <xref rid="F5" ref-type="fig">D</xref>). In the network view, the known and predicted interactions are obviously distinguished: the nodes of the known interactors are painted in red, while the nodes of the predicted interactors in blue. Considering network view for predicted interactions mainly act as discovery tool to find the potential upstream E3s/DUBs for the query protein (<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>), all known interactors were excluded from prediction results to avoid possible misleading. Clicking the node in the network view will lead to the page of supporting evidence information for the retrieved interactors (Figure <xref rid="F5" ref-type="fig">5E</xref> and <xref rid="F5" ref-type="fig">F</xref>). To help users focus on certain types of ESIs/DSIs in this network view, two filters were established: one is for data source allowing users to select known interactions to confirm the existent knowledge (Figure <xref rid="F5" ref-type="fig">5C</xref>), or to select the predicted interactions for discovery (Figure <xref rid="F5" ref-type="fig">5D</xref>); the other is for E3/DUB families (<xref rid="B18" ref-type="bibr">18</xref>) providing the rapid selection of a more specialized list of E3/DUB according to the user's needs. If users choose to show only the predicted interactors, UbiBrowser 2.0 provides two visualization modes: confidence mode and evidence mode. In the confidence mode, node size and edge width are positively proportional to the confidence score. In the evidence mode, various coloured edges between the central node and the surrounding nodes represent different types of supporting evidence (Figure <xref rid="F5" ref-type="fig">5D</xref>). Benefitting from the added ESIs/DSIs in multiple organisms, a function of ‘homology mapping’ was specially added in the network view page to help users investigate the orthologous ESI/DSI network of the query protein in other species (Figure <xref rid="F5" ref-type="fig">5</xref>C and D).</p>
    </sec>
    <sec id="SEC4-4">
      <title>Detailed information page for the known and predicted ESIs/DSIs</title>
      <sec id="SEC4-4-1">
        <title>Supporting literature information for the known ESIs/DSIs</title>
        <p>All known ESIs/DSIs were manually curated from literature, and the supporting literature information was provided for further study (Figure <xref rid="F5" ref-type="fig">5E</xref>). A brief introduction about E3/DUB and substrate, original literature PubMed ID and the supporting sentence are shown. The entries of E3/DUB and substrate in the supporting sentences were painted in yellow to provide an intuitive user experience. Furthermore, the user can click the hyperlink of PubMed ID to see the original paper.</p>
      </sec>
      <sec id="SEC4-4-2">
        <title>Supporting evidences for the predicted ESIs/DSIs</title>
        <p>To help users understand the basis for the prediction, we also re-designed the supporting evidence page for each predicted ESI/DSI (Figure <xref rid="F5" ref-type="fig">5F</xref>). The detailed information for the supporting evidences, including the enrichment domain pair (<xref rid="B27" ref-type="bibr">27</xref>), E3/DUB recognizing motif (<xref rid="B20" ref-type="bibr">20</xref>), the enriched GO term pair (<xref rid="B11" ref-type="bibr">11</xref>) and protein interaction network loop (<xref rid="B11" ref-type="bibr">11</xref>), was presented, together with the deriving known ESIs/DSIs with the enriched domain and GO term pair and E3/DUB recognizing motif. For example, the domain pair of ‘SPRY domain-CARD domain’ was predicted to mediate the ESI of ‘TRIM21-MAVS’ based on the real ESI of ‘TRIM25-DDX58’ (<xref rid="B28" ref-type="bibr">28</xref>), and this predicted domain pair of ‘SPRY domain-CARD domain’ can be validated by (<xref rid="B28" ref-type="bibr">28</xref>). Interestingly, the predicted ‘TRIM21-MAVS’ has been validated by Xue <italic toggle="yes">et al.</italic>, and the SPRY domain of TRIM21 was found to be the key domain for its interaction with MAVS (<xref rid="B29" ref-type="bibr">29</xref>). Considering that ESIs/DSIs in the non-human species were derived from human by homology mapping (<xref rid="B24" ref-type="bibr">24</xref>), a linkage of ‘Interolog in human’ was particularly added. When querying ESIs/DSIs of the non-human species, users can click on this linkage to explore the ortholog interaction information of these ESIs/DSIs in human.</p>
      </sec>
    </sec>
    <sec id="SEC4-5">
      <title>Download</title>
      <p>Some users would like to download the dataset for data mining rather than to query it via the web interface, therefore, we added the download function to improve UbiBrowser 2.0’s data accessibility. All known and predicted E3/DUB-substrate interactions can be downloaded from the ‘Download’ page in bulk, together with their supporting evidences. All files are provided in a tab-delimited text format.</p>
    </sec>
    <sec id="SEC4-6">
      <title>API</title>
      <p>To facilitate programmatic access and cross-references, we created an application programming interface (API). The API is called by constructing a URL that contains the selected parameters (including type of the request, the desired output format and the input item), and returns the query result in a computer-readable XML format for program, or a visible hypertext page for external databases cross-references (please refer to the document in our website for the detailed information).</p>
    </sec>
    <sec id="SEC4-7">
      <title>CASE STUDIES</title>
      <p>UbiBrowser 1.0 (<xref rid="B11" ref-type="bibr">11</xref>) has been used as a discovery tool to study protein homeostasis regulation mechanism (<xref rid="B5" ref-type="bibr">5</xref>) from the aspect of E3–substrate interaction. Some of the predicted human ESIs by UbiBrowser 1.0 have been experimentally validated by independent studies. Examples include the discovery of E3 ligase STUB as a novel regulator for ERRα protein stability in osteoclasts (<xref rid="B12" ref-type="bibr">12</xref>), and the finding of MDM2 as the E3 ligase for ACE2 (the receptor for SARS-CoV-2 to enter host cells) (<xref rid="B13" ref-type="bibr">13</xref>). Benefiting from the added ESI/DSI datasets in multiple organisms, users can further explore the delicate protein homeostasis regulation mechanism from two opposing directions of ubiquitination and deubiquitination.</p>
    </sec>
    <sec id="SEC4-8">
      <title>Case study I: exploring the homeostasis regulation mechanism for proteins in two opposing directions</title>
      <p>As we know, loss of protein homeostasis can influence disease-related proteins’ abundance (<xref rid="B5" ref-type="bibr">5</xref>). The homeostasis regulatory mechanism of proteins in disease signaling cascades (from receptors to signaling proteins and transcriptional factors) can be explored by UbiBrowser 2.0 in two opposing directions (Figure <xref rid="F6" ref-type="fig">6</xref>).</p>
      <fig position="float" id="F6">
        <label>Figure 6.</label>
        <caption>
          <p>Use cases for UbiBrowser 2.0: exploration of the E3 ligase and deubiquitinase determining the bidirectional regulation of disease signaling cascades proteins. Confidence scores on graph were assigned by UbiBrowser 2.0. (<bold>A</bold>) WWP1-EGFR-STAMBP. MAPK signaling was predicted to be regulated by the axis of WWP1-EGFR-STAMBP, which was validated by (<xref rid="B30" ref-type="bibr">30</xref>) and (<xref rid="B31" ref-type="bibr">31</xref>). (<bold>B</bold>) NEDD4-TBK1-CYLD. NEDD4 and CYLD were validated to catalyze ploy-ubiquitination of TBK1 and negatively regulate type I IFN signaling (<xref rid="B32" ref-type="bibr">32</xref>,<xref rid="B33" ref-type="bibr">33</xref>), while CYLD was observed to remove Lys 63-linked polyubiquitin from TBK1 (<xref rid="B33" ref-type="bibr">33</xref>). (<bold>C</bold>) HECW1-SMAD4-USP4. For SMAD4, the predicted E3 HECW1 was validated to promote the metastasis of non-small cell lung cancer cells through mediating the ubiquitination of SMAD4 (<xref rid="B34" ref-type="bibr">34</xref>), while the predicted DUB USP4 to inhibit SMAD4 monoubiquitination and to promote activin and BMP signaling (<xref rid="B35" ref-type="bibr">35</xref>). Ub: ubiquitin.</p>
        </caption>
        <graphic xlink:href="gkab962fig6" position="float"/>
      </fig>
      <sec id="SEC4-8-1">
        <title>WWP1-EGFR-STAMBP</title>
        <p>Epidermal growth factor receptor (EGFR) controls the growth and survival of epithelial cells. The dysregulation of EGFR degradation was supposed to accelerate tumor initiation and progression, thus exploring the E3/DUB-mediated ubiquitination regulation of EGFR is promising for cancer therapy (<xref rid="B30" ref-type="bibr">30</xref>). By searching the potential E3 and DUB for EGFR in UbiBrowser 2.0, we speculated that WWP1 E3 ligase with confidence score of 0.949 might be a negative regulator of EGFR abundance, while the deubiquitinase STAMBP with confidence score of 0.852 might stabilize EGFR (Figure <xref rid="F6" ref-type="fig">6A</xref>). The recent studies validated these hypotheses: WWP1-induced EGFR ubiquitination was found to be a decisive signal for EGFR recycling (<xref rid="B30" ref-type="bibr">30</xref>); meanwhile, the overexpression of STAMBP can promote the stabilization of EGFR, and promote tumor progression (<xref rid="B31" ref-type="bibr">31</xref>). Hence, the predicted STAMBP provides novel potential targets for cancer therapy.</p>
      </sec>
      <sec id="SEC4-8-2">
        <title>NEDD4-TBK1-CYLD</title>
        <p>Against viral infection, TANK-binding kinase 1 (TBK1) triggers phosphorylation and translocation of IFN-regulatory factor 3 (IRF3), which then activates transcriptional activation of type I IFNs and initiates antiviral responses (<xref rid="B32" ref-type="bibr">32</xref>). In UbiBrowser 2.0, NEDD4 and CYLD were predicted as the high-confidence E3 (score: 0.886) and DUB (score: 0.877) for TBK1 (Figure <xref rid="F6" ref-type="fig">6B</xref>), respectively. In fact, it has been found that NEDD4 catalyzes ploy-ubiquitination of TBK1 and negatively regulates type I IFN signaling to mediate the homeostasis of innate immunity (<xref rid="B32" ref-type="bibr">32</xref>). Meanwhile, CYLD was also observed to remove Lys 63-linked polyubiquitin from TBK1, and can negatively regulate innate antiviral response (<xref rid="B33" ref-type="bibr">33</xref>).</p>
      </sec>
      <sec id="SEC4-8-3">
        <title>HECW1-SMAD4-USP4</title>
        <p>The transcriptional factor of SMAD4 (SMAD family member 4) can be activated by TGFβ (transforming growth factor-β) and accumulates in the nucleus, which is involved in the tumor invasion and distant metastasis (<xref rid="B34" ref-type="bibr">34</xref>). By UbiBrowser 2.0, the E3 ligase HECW1 (score: 0.889) and the deubiquitinase USP4 (score: 0.894) were predicted to be potential regulators for SMAD4 (Figure <xref rid="F6" ref-type="fig">6C</xref>). Interestingly, these speculations have been confirmed that HECW1 can promote the proliferation, migration and invasion of cancer cells by inducing the ubiquitination and degradation of SMAD4 (<xref rid="B34" ref-type="bibr">34</xref>), while USP4 can mediate the deubiquitination of SMAD4, leading to the expression of apoptotic proteins (<xref rid="B35" ref-type="bibr">35</xref>).</p>
      </sec>
    </sec>
    <sec id="SEC4-9">
      <title>Case study II: investigating the delicate regulation of critical proteins in non-human physiological processes</title>
      <p><italic toggle="yes">Drosophila melanogaster</italic> is a powerful, in vivo system to model Parkinson's disease (PD) pathobiology for its well-defined nerve system. It was found that ER-mitochondria contacts are altered under PD pathological conditions (<xref rid="B36" ref-type="bibr">36</xref>). The mitofusin family proteins were found to mediate mitochondrial fusion, and enrich at contact sites between ER and mitochondria to modulate ER-mitochondria cross-talk in vitro. Interestingly, parkin is predicted to be the highest-ranked E3 of mitofusin in UbiBrowser 2.0 (rank = 1). In fact, researches have shown that parkin can ubiquitinate mitofusin, and promote the formation of ER-mitochondria contacts sites, which was related to the locomotor deficits in PD (<xref rid="B37" ref-type="bibr">37</xref>). On the other side, USP8 was predicted to be the deubiquitinase of mitofusin (rank = 12), and the experiment validated that genetic and pharmacological inhibition of USP8 can down-regulate the elevated mitofusin protein levels in parkin deficient fly models (<xref rid="B38" ref-type="bibr">38</xref>).</p>
    </sec>
  </sec>
  <sec sec-type="conclusions" id="SEC5">
    <title>CONCLUSION AND FUTURE</title>
    <p>UbiBrowser 2.0 has a great improvement from version 1.0 (<xref rid="B11" ref-type="bibr">11</xref>). Extensive manual curation was implemented to extract the known ESIs/DSIs from PubMed abstracts. Two well-recognized algorithms of ‘naïve Bayesian classifier’ and ‘interolog mapping’ were integrated to predict proteome-wide ESI/DSI networks (<xref rid="B11" ref-type="bibr">11</xref>,<xref rid="B24" ref-type="bibr">24</xref>). Using this improved protocol, we identified 5035 known, and more than two million high confidence predicted ubiquitin ligase/deubiquitinase–substrate interactions in multiple organisms, with &gt;210-fold increase in total data volume. UbiBrowser 2.0 has the following advantages: (i) it comprises the most known ESIs/DSIs compared to the related databases; (ii) it provides proteome-wide E3 ligase/deubiquitinase–substrate predicted interactions in 39 eukaryotes; (iii) it allows studying proteins’ upstream E3 ligases and deubiquitinases simultaneously; (iv) it presents a uniform confidence scoring system to rank the predicted interacting partners of the query protein across multiple organisms; (v) we optimized web interfaces to increase the convenience for users to search, browse and visualize known and predicted ESIs/DSIs. In the future, we will continue to update and maintain our database. E3/DUB-substrate interaction datasets will be expanded to cover all eukaryotic organisms. Cross-references to other public databases will be added to satisfy different requirements. Patient-derived multi-omics datasets will be integrated for the potential biological roles and clinical utility of ubiquitination. We believe that the database of UbiBrowser will be a comprehensive and useful resource for the ubiquitination community.</p>
  </sec>
  <sec sec-type="data-availability" id="SEC6">
    <title>DATA AVAILABILITY</title>
    <p>UbiBrowser 2.0 can be accessed at <ext-link xlink:href="http://ubibrowser.ncpsb.org.cn" ext-link-type="uri">http://ubibrowser.ncpsb.org.cn</ext-link>.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>gkab962_Supplemental_Files</label>
      <media xlink:href="gkab962_supplemental_files.zip">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack id="ACK1">
    <title>ACKNOWLEDGEMENTS</title>
    <p>We gratefully acknowledge UbiNet, hUbiquitome and Di Chen <italic toggle="yes">et al.</italic> for their generously sharing of the ubiquitination datasets. We also thank the bioinformatics platform at Phoenix Center for the strong and stable IT support.</p>
  </ack>
  <sec id="SEC7">
    <title>SUPPLEMENTARY DATA</title>
    <p><ext-link xlink:href="https://academic.oup.com/nar/article-lookup/doi/10.1093/nar/gkab962#supplementary-data" ext-link-type="uri">Supplementary Data</ext-link> are available at NAR Online.</p>
  </sec>
  <sec id="SEC8">
    <title>FUNDING</title>
    <p>National Natural Science Foundation of China [32088101, 31871341]; National key Research and Development Program of China [2020YFE0202200]; Beijing Talents Foundation [to D.L.]. Funding for open access charge: National Natural Science Foundation of China [32088101].</p>
    <p><italic toggle="yes">Conflict of interest statement</italic>. None declared.</p>
  </sec>
  <ref-list id="REF1">
    <title>REFERENCES</title>
    <ref id="B1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Popovic</surname><given-names>D.</given-names></string-name>, <string-name><surname>Vucic</surname><given-names>D.</given-names></string-name>, <string-name><surname>Dikic</surname><given-names>I.</given-names></string-name></person-group><article-title>Ubiquitination in disease pathogenesis and treatment</article-title>. <source>Nat. Med.</source><year>2014</year>; <volume>20</volume>:<fpage>1242</fpage>–<lpage>1253</lpage>.<pub-id pub-id-type="pmid">25375928</pub-id></mixed-citation>
    </ref>
    <ref id="B2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sun</surname><given-names>T.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>Q.</given-names></string-name></person-group><article-title>The role of ubiquitination and deubiquitination in cancer metabolism</article-title>. <source>Mol. Cancer</source>. <year>2020</year>; <volume>19</volume>:<fpage>146</fpage>.<pub-id pub-id-type="pmid">33004065</pub-id></mixed-citation>
    </ref>
    <ref id="B3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Leroy</surname><given-names>E.</given-names></string-name>, <string-name><surname>Boyer</surname><given-names>R.</given-names></string-name>, <string-name><surname>Auburger</surname><given-names>G.</given-names></string-name>, <string-name><surname>Leube</surname><given-names>B.</given-names></string-name>, <string-name><surname>Ulm</surname><given-names>G.</given-names></string-name>, <string-name><surname>Mezey</surname><given-names>E.</given-names></string-name>, <string-name><surname>Harta</surname><given-names>G.</given-names></string-name>, <string-name><surname>Brownstein</surname><given-names>M.J.</given-names></string-name>, <string-name><surname>Jonnalagada</surname><given-names>S.</given-names></string-name>, <string-name><surname>Chernova</surname><given-names>T.</given-names></string-name><etal>et al</etal>.</person-group><article-title>The ubiquitin pathway in Parkinson's disease</article-title>. <source>Nature</source>. <year>1998</year>; <volume>395</volume>:<fpage>451</fpage>–<lpage>452</lpage>.<pub-id pub-id-type="pmid">9774100</pub-id></mixed-citation>
    </ref>
    <ref id="B4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Song</surname><given-names>S.</given-names></string-name>, <string-name><surname>Jung</surname><given-names>Y.K.</given-names></string-name></person-group><article-title>Alzheimer's disease meets the ubiquitin-proteasome system</article-title>. <source>Trends Mol. Med.</source><year>2004</year>; <volume>10</volume>:<fpage>565</fpage>–<lpage>570</lpage>.<pub-id pub-id-type="pmid">15519283</pub-id></mixed-citation>
    </ref>
    <ref id="B5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Deng</surname><given-names>L.</given-names></string-name>, <string-name><surname>Meng</surname><given-names>T.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>L.</given-names></string-name>, <string-name><surname>Wei</surname><given-names>W.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>P.</given-names></string-name></person-group><article-title>The role of ubiquitination in tumorigenesis and targeted drug discovery</article-title>. <source>Signal Transd. Targeted Ther</source>. <year>2020</year>; <volume>5</volume>:<fpage>11</fpage>.</mixed-citation>
    </ref>
    <ref id="B6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Burkhart</surname><given-names>R.A.</given-names></string-name>, <string-name><surname>Peng</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Norris</surname><given-names>Z.A.</given-names></string-name>, <string-name><surname>Tholey</surname><given-names>R.M.</given-names></string-name>, <string-name><surname>Talbott</surname><given-names>V.A.</given-names></string-name>, <string-name><surname>Liang</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Ai</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Miller</surname><given-names>K.</given-names></string-name>, <string-name><surname>Lal</surname><given-names>S.</given-names></string-name>, <string-name><surname>Cozzitorto</surname><given-names>J.A.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Mitoxantrone targets human ubiquitin-specific peptidase 11 (USP11) and is a potent inhibitor of pancreatic cancer cell survival</article-title>. <source>Mol. Cancer Res.</source><year>2013</year>; <volume>11</volume>:<fpage>901</fpage>–<lpage>911</lpage>.<pub-id pub-id-type="pmid">23696131</pub-id></mixed-citation>
    </ref>
    <ref id="B7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Loch</surname><given-names>C.M.</given-names></string-name>, <string-name><surname>Strickler</surname><given-names>J.E.</given-names></string-name></person-group><article-title>A microarray of ubiquitylated proteins for profiling deubiquitylase activity reveals the critical roles of both chain and substrate</article-title>. <source>Biochim. Biophys. Acta, Mol. Cell Res.</source><year>2012</year>; <volume>1823</volume>:<fpage>2069</fpage>–<lpage>2078</lpage>.</mixed-citation>
    </ref>
    <ref id="B8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yen</surname><given-names>H.C.</given-names></string-name>, <string-name><surname>Elledge</surname><given-names>S.J.</given-names></string-name></person-group><article-title>Identification of SCF ubiquitin ligase substrates by global protein stability profiling</article-title>. <source>Science</source>. <year>2008</year>; <volume>322</volume>:<fpage>923</fpage>–<lpage>929</lpage>.<pub-id pub-id-type="pmid">18988848</pub-id></mixed-citation>
    </ref>
    <ref id="B9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yumimoto</surname><given-names>K.</given-names></string-name>, <string-name><surname>Matsumoto</surname><given-names>M.</given-names></string-name>, <string-name><surname>Oyamada</surname><given-names>K.</given-names></string-name>, <string-name><surname>Moroishi</surname><given-names>T.</given-names></string-name>, <string-name><surname>Nakayama</surname><given-names>K.I.</given-names></string-name></person-group><article-title>Comprehensive identification of substrates for F-box proteins by differential proteomics analysis</article-title>. <source>J. Proteome Res.</source><year>2012</year>; <volume>11</volume>:<fpage>3175</fpage>–<lpage>3185</lpage>.<pub-id pub-id-type="pmid">22524983</pub-id></mixed-citation>
    </ref>
    <ref id="B10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Guo</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>X.</given-names></string-name>, <string-name><surname>Li</surname><given-names>H.</given-names></string-name>, <string-name><surname>Gao</surname><given-names>Y.</given-names></string-name></person-group><article-title>Screening E3 substrates using a live phage display library</article-title>. <source>PLoS One</source>. <year>2013</year>; <volume>8</volume>:<fpage>e76622</fpage>.<pub-id pub-id-type="pmid">24124579</pub-id></mixed-citation>
    </ref>
    <ref id="B11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Xie</surname><given-names>P.</given-names></string-name>, <string-name><surname>Lu</surname><given-names>L.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Diao</surname><given-names>L.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Guo</surname><given-names>F.</given-names></string-name>, <string-name><surname>He</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Huang</surname><given-names>Q.</given-names></string-name><etal>et al</etal>.</person-group><article-title>An integrated bioinformatics platform for investigating the human E3 ubiquitin ligase-substrate interaction network</article-title>. <source>Nat. Commun.</source><year>2017</year>; <volume>8</volume>:<fpage>347</fpage>.<pub-id pub-id-type="pmid">28839186</pub-id></mixed-citation>
    </ref>
    <ref id="B12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zheng</surname><given-names>Z.G.</given-names></string-name>, <string-name><surname>Cheng</surname><given-names>H.M.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>Y.P.</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>S.T.</given-names></string-name>, <string-name><surname>Thu</surname><given-names>P.M.</given-names></string-name>, <string-name><surname>Li</surname><given-names>H.J.</given-names></string-name>, <string-name><surname>Li</surname><given-names>P.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>X.</given-names></string-name></person-group><article-title>Dual targeting of SREBP2 and ERRalpha by carnosic acid suppresses RANKL-mediated osteoclastogenesis and prevents ovariectomy-induced bone loss</article-title>. <source>Cell Death Differ.</source><year>2020</year>; <volume>27</volume>:<fpage>2048</fpage>–<lpage>2065</lpage>.<pub-id pub-id-type="pmid">31907393</pub-id></mixed-citation>
    </ref>
    <ref id="B13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shen</surname><given-names>H.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>C.</given-names></string-name>, <string-name><surname>Jain</surname><given-names>P.P.</given-names></string-name>, <string-name><surname>Xiong</surname><given-names>M.</given-names></string-name>, <string-name><surname>Shi</surname><given-names>X.</given-names></string-name>, <string-name><surname>Lei</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>S.</given-names></string-name>, <string-name><surname>Yin</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Thistlethwaite</surname><given-names>P.A.</given-names></string-name><etal>et al</etal>.</person-group><article-title>MDM2-mediated ubiquitination of angiotensin-converting enzyme 2 contributes to the development of pulmonary arterial h-ypertension</article-title>. <source>Circulation</source>. <year>2020</year>; <volume>142</volume>:<fpage>1190</fpage>–<lpage>1204</lpage>.<pub-id pub-id-type="pmid">32755395</pub-id></mixed-citation>
    </ref>
    <ref id="B14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Du</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>N.</given-names></string-name>, <string-name><surname>Lu</surname><given-names>M.</given-names></string-name>, <string-name><surname>Li</surname><given-names>T.</given-names></string-name></person-group><article-title>hUbiquitome: a database of experimentally verified ubiquitination cascades in humans</article-title>. <source>Database</source>. <year>2011</year>; <volume>2011</volume>:<fpage>bar055</fpage>.<pub-id pub-id-type="pmid">22134927</pub-id></mixed-citation>
    </ref>
    <ref id="B15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname><given-names>D.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>X.</given-names></string-name>, <string-name><surname>Xia</surname><given-names>T.</given-names></string-name>, <string-name><surname>Tekcham</surname><given-names>D.S.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>W.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>H.</given-names></string-name>, <string-name><surname>Li</surname><given-names>T.</given-names></string-name>, <string-name><surname>Lu</surname><given-names>C.</given-names></string-name>, <string-name><surname>Ning</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>X.</given-names></string-name><etal>et al</etal>.</person-group><article-title>A multidimensional characterization of E3 ubiquitin ligase and substrate interaction network</article-title>. <source>iScience</source>. <year>2019</year>; <volume>16</volume>:<fpage>177</fpage>–<lpage>191</lpage>.<pub-id pub-id-type="pmid">31181401</pub-id></mixed-citation>
    </ref>
    <ref id="B16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname><given-names>D.</given-names></string-name>, <string-name><surname>Ning</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>H.</given-names></string-name>, <string-name><surname>Lu</surname><given-names>C.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>X.</given-names></string-name>, <string-name><surname>Xia</surname><given-names>T.</given-names></string-name>, <string-name><surname>Qi</surname><given-names>H.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>W.</given-names></string-name>, <string-name><surname>Ling</surname><given-names>T.</given-names></string-name>, <string-name><surname>Guo</surname><given-names>X.</given-names></string-name><etal>et al</etal>.</person-group><article-title>An integrative pan-cancer analysis of biological and clinical impacts underlying ubiquitin-specific-processing proteases</article-title>. <source>Oncogene</source>. <year>2020</year>; <volume>39</volume>:<fpage>587</fpage>–<lpage>602</lpage>.<pub-id pub-id-type="pmid">31511647</pub-id></mixed-citation>
    </ref>
    <ref id="B17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>S.</given-names></string-name>, <string-name><surname>Jhong</surname><given-names>J.H.</given-names></string-name>, <string-name><surname>Pang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Huang</surname><given-names>K.Y.</given-names></string-name>, <string-name><surname>Li</surname><given-names>S.</given-names></string-name>, <string-name><surname>Lee</surname><given-names>T.Y.</given-names></string-name></person-group><article-title>UbiNet 2.0: a verified, classified, annotated and updated database of E3 ubiquitin ligase-substrate interactions</article-title>. <source>Database</source>. <year>2021</year>; <volume>2021</volume>:<fpage>baab010</fpage>.<pub-id pub-id-type="pmid">33693667</pub-id></mixed-citation>
    </ref>
    <ref id="B18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhou</surname><given-names>J.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Lin</surname><given-names>S.</given-names></string-name>, <string-name><surname>Guo</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Deng</surname><given-names>W.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Guo</surname><given-names>A.</given-names></string-name>, <string-name><surname>Xue</surname><given-names>Y.</given-names></string-name></person-group><article-title>iUUCD 2.0: an update with rich annotations for ubiquitin and ubiquitin-like conjugations</article-title>. <source>Nucleic Acids Res.</source><year>2018</year>; <volume>46</volume>:<fpage>D447</fpage>–<lpage>D453</lpage>.<pub-id pub-id-type="pmid">29106644</pub-id></mixed-citation>
    </ref>
    <ref id="B19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><collab>Gene Ontology Consortium</collab><article-title>Gene Ontology Consortium: going forward</article-title>. <source>Nucleic. Acids. Res.</source><year>2015</year>; <volume>43</volume>:<fpage>D1049</fpage>–<lpage>D1056</lpage>.<pub-id pub-id-type="pmid">25428369</pub-id></mixed-citation>
    </ref>
    <ref id="B20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schwartz</surname><given-names>D.</given-names></string-name>, <string-name><surname>Gygi</surname><given-names>S.P.</given-names></string-name></person-group><article-title>An iterative statistical approach to the identification of protein phosphorylation motifs from large-scale data sets</article-title>. <source>Nat. Biotechnol.</source><year>2005</year>; <volume>23</volume>:<fpage>1391</fpage>–<lpage>1398</lpage>.<pub-id pub-id-type="pmid">16273072</pub-id></mixed-citation>
    </ref>
    <ref id="B21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Keshava Prasad</surname><given-names>T.S.</given-names></string-name>, <string-name><surname>Goel</surname><given-names>R.</given-names></string-name>, <string-name><surname>Kandasamy</surname><given-names>K.</given-names></string-name>, <string-name><surname>Keerthikumar</surname><given-names>S.</given-names></string-name>, <string-name><surname>Kumar</surname><given-names>S.</given-names></string-name>, <string-name><surname>Mathivanan</surname><given-names>S.</given-names></string-name>, <string-name><surname>Telikicherla</surname><given-names>D.</given-names></string-name>, <string-name><surname>Raju</surname><given-names>R.</given-names></string-name>, <string-name><surname>Shafreen</surname><given-names>B.</given-names></string-name>, <string-name><surname>Venugopal</surname><given-names>A.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Human Protein Reference Database–2009 update</article-title>. <source>Nucleic Acids Res.</source><year>2009</year>; <volume>37</volume>:<fpage>D767</fpage>–<lpage>772</lpage>.<pub-id pub-id-type="pmid">18988627</pub-id></mixed-citation>
    </ref>
    <ref id="B22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Baldi</surname><given-names>P.</given-names></string-name>, <string-name><surname>Brunak</surname><given-names>S.</given-names></string-name>, <string-name><surname>Chauvin</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Andersen</surname><given-names>C.A.F.</given-names></string-name>, <string-name><surname>Nielsen</surname><given-names>H.</given-names></string-name></person-group><article-title>Assessing the accuracy of prediction algorithms for classification: an overview</article-title>. <source>Bioinformatics</source>. <year>2000</year>; <volume>16</volume>:<fpage>412</fpage>–<lpage>424</lpage>.<pub-id pub-id-type="pmid">10871264</pub-id></mixed-citation>
    </ref>
    <ref id="B23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zuin</surname><given-names>A.</given-names></string-name>, <string-name><surname>Isasa</surname><given-names>M.</given-names></string-name>, <string-name><surname>Crosas</surname><given-names>B.</given-names></string-name></person-group><article-title>Ubiquitin signaling: extreme conservation as a source of diversity</article-title>. <source>Cells</source>. <year>2014</year>; <volume>3</volume>:<fpage>690</fpage>–<lpage>701</lpage>.<pub-id pub-id-type="pmid">25014160</pub-id></mixed-citation>
    </ref>
    <ref id="B24">
      <label>24.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Matthews</surname><given-names>L.R.</given-names></string-name>, <string-name><surname>Vaglio</surname><given-names>P.</given-names></string-name>, <string-name><surname>Reboul</surname><given-names>J.</given-names></string-name>, <string-name><surname>Ge</surname><given-names>H.</given-names></string-name>, <string-name><surname>Davis</surname><given-names>B.P.</given-names></string-name>, <string-name><surname>Garrels</surname><given-names>J.</given-names></string-name>, <string-name><surname>Vincent</surname><given-names>S.</given-names></string-name>, <string-name><surname>Vidal</surname><given-names>M.</given-names></string-name></person-group><article-title>Identification of potential interaction networks using sequence-based searches for conserved protein-protein interactions or “interologs</article-title>. <source>Genome Res.</source><year>2001</year>; <volume>11</volume>:<fpage>2120</fpage>–<lpage>2126</lpage>.<pub-id pub-id-type="pmid">11731503</pub-id></mixed-citation>
    </ref>
    <ref id="B25">
      <label>25.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sonnhammer</surname><given-names>E.L.L.</given-names></string-name>, <string-name><surname>Östlund</surname><given-names>G.</given-names></string-name></person-group><article-title>InParanoid 8: orthology analysis between 273 proteomes, mostly eukaryotic</article-title>. <source>Nucleic Acids Res.</source><year>2014</year>; <volume>43</volume>:<fpage>D234</fpage>–<lpage>D239</lpage>.<pub-id pub-id-type="pmid">25429972</pub-id></mixed-citation>
    </ref>
    <ref id="B26">
      <label>26.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mistry</surname><given-names>J.</given-names></string-name>, <string-name><surname>Chuguransky</surname><given-names>S.</given-names></string-name>, <string-name><surname>Williams</surname><given-names>L.</given-names></string-name>, <string-name><surname>Qureshi</surname><given-names>M.</given-names></string-name>, <string-name><surname>Salazar</surname><given-names>G.A.</given-names></string-name>, <string-name><surname>Sonnhammer</surname><given-names>E.L.L.</given-names></string-name>, <string-name><surname>Tosatto</surname><given-names>S.C.E.</given-names></string-name>, <string-name><surname>Paladin</surname><given-names>L.</given-names></string-name>, <string-name><surname>Raj</surname><given-names>S.</given-names></string-name>, <string-name><surname>Richardson</surname><given-names>L.J.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Pfam: the protein families database in 2021</article-title>. <source>Nucleic. Acids. Res.</source><year>2021</year>; <volume>49</volume>:<fpage>D412</fpage>–<lpage>D419</lpage>.<pub-id pub-id-type="pmid">33125078</pub-id></mixed-citation>
    </ref>
    <ref id="B27">
      <label>27.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rhodes</surname><given-names>D.R.</given-names></string-name>, <string-name><surname>Tomlins</surname><given-names>S.A.</given-names></string-name>, <string-name><surname>Varambally</surname><given-names>S.</given-names></string-name>, <string-name><surname>Mahavisno</surname><given-names>V.</given-names></string-name>, <string-name><surname>Barrette</surname><given-names>T.</given-names></string-name>, <string-name><surname>Kalyana-Sundaram</surname><given-names>S.</given-names></string-name>, <string-name><surname>Ghosh</surname><given-names>D.</given-names></string-name>, <string-name><surname>Pandey</surname><given-names>A.</given-names></string-name>, <string-name><surname>Chinnaiyan</surname><given-names>A.M.</given-names></string-name></person-group><article-title>Probabilistic model of the human protein-protein interaction network</article-title>. <source>Nat. Biotechnol.</source><year>2005</year>; <volume>23</volume>:<fpage>951</fpage>–<lpage>959</lpage>.<pub-id pub-id-type="pmid">16082366</pub-id></mixed-citation>
    </ref>
    <ref id="B28">
      <label>28.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gack</surname><given-names>M.U.</given-names></string-name>, <string-name><surname>Shin</surname><given-names>Y.C.</given-names></string-name>, <string-name><surname>Joo</surname><given-names>C.H.</given-names></string-name>, <string-name><surname>Urano</surname><given-names>T.</given-names></string-name>, <string-name><surname>Liang</surname><given-names>C.</given-names></string-name>, <string-name><surname>Sun</surname><given-names>L.</given-names></string-name>, <string-name><surname>Takeuchi</surname><given-names>O.</given-names></string-name>, <string-name><surname>Akira</surname><given-names>S.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Inoue</surname><given-names>S.</given-names></string-name><etal>et al</etal>.</person-group><article-title>TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity</article-title>. <source>Nature</source>. <year>2007</year>; <volume>446</volume>:<fpage>916</fpage>–<lpage>920</lpage>.<pub-id pub-id-type="pmid">17392790</pub-id></mixed-citation>
    </ref>
    <ref id="B29">
      <label>29.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xue</surname><given-names>B.</given-names></string-name>, <string-name><surname>Li</surname><given-names>H.</given-names></string-name>, <string-name><surname>Guo</surname><given-names>M.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Zou</surname><given-names>X.</given-names></string-name>, <string-name><surname>Deng</surname><given-names>R.</given-names></string-name>, <string-name><surname>Li</surname><given-names>G.</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>H.</given-names></string-name>, <string-name><surname>Ou</surname><given-names>J.H.J.</given-names></string-name></person-group><article-title>TRIM21 promotes innate Immune response to RNA viral infection through Lys27-linked polyubiquitination of MAVS</article-title>. <source>J. Virol.</source><year>2018</year>; <volume>92</volume>:<fpage>e00321-18</fpage>.<pub-id pub-id-type="pmid">29743353</pub-id></mixed-citation>
    </ref>
    <ref id="B30">
      <label>30.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yu</surname><given-names>J.J.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>D.D.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>X.X.</given-names></string-name>, <string-name><surname>Cui</surname><given-names>B.</given-names></string-name>, <string-name><surname>Tan</surname><given-names>F.W.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Li</surname><given-names>K.</given-names></string-name>, <string-name><surname>Shang</surname><given-names>S.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>C.</given-names></string-name>, <string-name><surname>Lv</surname><given-names>X.X.</given-names></string-name><etal>et al</etal>.</person-group><article-title>TRIB3-EGFR interaction promotes lung cancer progression and defines a therapeutic target</article-title>. <source>Nat. Commun.</source><year>2020</year>; <volume>11</volume>:<fpage>3660</fpage>.<pub-id pub-id-type="pmid">32694521</pub-id></mixed-citation>
    </ref>
    <ref id="B31">
      <label>31.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xu</surname><given-names>H.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>X.</given-names></string-name>, <string-name><surname>Xuan</surname><given-names>X.</given-names></string-name>, <string-name><surname>Wu</surname><given-names>D.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>X.</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Ma</surname><given-names>C.</given-names></string-name>, <string-name><surname>Li</surname><given-names>D.</given-names></string-name></person-group><article-title>STAMBP promotes lung adenocarcinoma metastasis by regulating the EGFR/MAPK signaling pathway</article-title>. <source>Neoplasia</source>. <year>2021</year>; <volume>23</volume>:<fpage>607</fpage>–<lpage>623</lpage>.<pub-id pub-id-type="pmid">34102455</pub-id></mixed-citation>
    </ref>
    <ref id="B32">
      <label>32.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xie</surname><given-names>W.</given-names></string-name>, <string-name><surname>Jin</surname><given-names>S.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>C.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>S.</given-names></string-name>, <string-name><surname>Wu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Songyang</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Cui</surname><given-names>J.</given-names></string-name></person-group><article-title>Selective autophagy controls the stability of TBK1 via NEDD4 to balance host defense</article-title>. <source>Cell Death Differ.</source><year>2021</year>; <pub-id pub-id-type="doi">10.1038/s41418-021-00833-9</pub-id>.</mixed-citation>
    </ref>
    <ref id="B33">
      <label>33.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Friedman</surname><given-names>C.S.</given-names></string-name>, <string-name><surname>O’Donnell</surname><given-names>M.A.</given-names></string-name>, <string-name><surname>Legarda-Addison</surname><given-names>D.</given-names></string-name>, <string-name><surname>Ng</surname><given-names>A.</given-names></string-name>, <string-name><surname>Cardenas</surname><given-names>W.B.</given-names></string-name>, <string-name><surname>Yount</surname><given-names>J.S.</given-names></string-name>, <string-name><surname>Moran</surname><given-names>T.M.</given-names></string-name>, <string-name><surname>Basler</surname><given-names>C.F.</given-names></string-name>, <string-name><surname>Komuro</surname><given-names>A.</given-names></string-name>, <string-name><surname>Horvath</surname><given-names>C.M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response</article-title>. <source>EMBO Rep.</source><year>2008</year>; <volume>9</volume>:<fpage>930</fpage>–<lpage>936</lpage>.<pub-id pub-id-type="pmid">18636086</pub-id></mixed-citation>
    </ref>
    <ref id="B34">
      <label>34.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lu</surname><given-names>C.</given-names></string-name>, <string-name><surname>Ning</surname><given-names>G.</given-names></string-name>, <string-name><surname>Si</surname><given-names>P.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>C.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>W.</given-names></string-name>, <string-name><surname>Ge</surname><given-names>W.</given-names></string-name>, <string-name><surname>Cui</surname><given-names>K.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>R.</given-names></string-name>, <string-name><surname>Ge</surname><given-names>S.</given-names></string-name></person-group><article-title>E3 ubiquitin ligase HECW1 promotes the metastasis of non-small cell lung cancer cells through mediating the ubiquitination of Smad4</article-title>. <source>Biochem. Cell. Biol.</source><year>2021</year>; <volume>99</volume>:<fpage>675</fpage>–<lpage>681</lpage>.<pub-id pub-id-type="pmid">33529121</pub-id></mixed-citation>
    </ref>
    <ref id="B35">
      <label>35.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhou</surname><given-names>F.</given-names></string-name>, <string-name><surname>Xie</surname><given-names>F.</given-names></string-name>, <string-name><surname>Jin</surname><given-names>K.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Clerici</surname><given-names>M.</given-names></string-name>, <string-name><surname>Gao</surname><given-names>R.</given-names></string-name>, <string-name><surname>van Dinther</surname><given-names>M.</given-names></string-name>, <string-name><surname>Sixma</surname><given-names>T.K.</given-names></string-name>, <string-name><surname>Huang</surname><given-names>H.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>L.</given-names></string-name><etal>et al</etal>.</person-group><article-title>USP4 inhibits SMAD4 monoubiquitination and promotes activin and BMP signaling</article-title>. <source>EMBO J.</source><year>2017</year>; <volume>36</volume>:<fpage>1623</fpage>–<lpage>1639</lpage>.<pub-id pub-id-type="pmid">28468752</pub-id></mixed-citation>
    </ref>
    <ref id="B36">
      <label>36.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Basso</surname><given-names>V.</given-names></string-name>, <string-name><surname>Marchesan</surname><given-names>E.</given-names></string-name>, <string-name><surname>Peggion</surname><given-names>C.</given-names></string-name>, <string-name><surname>Chakraborty</surname><given-names>J.</given-names></string-name>, <string-name><surname>von Stockum</surname><given-names>S.</given-names></string-name>, <string-name><surname>Giacomello</surname><given-names>M.</given-names></string-name>, <string-name><surname>Ottolini</surname><given-names>D.</given-names></string-name>, <string-name><surname>Debattisti</surname><given-names>V.</given-names></string-name>, <string-name><surname>Caicci</surname><given-names>F.</given-names></string-name>, <string-name><surname>Tasca</surname><given-names>E.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Regulation of ER-mitochondria contacts by Parkin via Mfn2</article-title>. <source>Pharmacol. Res.</source><year>2018</year>; <volume>138</volume>:<fpage>43</fpage>–<lpage>56</lpage>.<pub-id pub-id-type="pmid">30219582</pub-id></mixed-citation>
    </ref>
    <ref id="B37">
      <label>37.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xiong</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Yu</surname><given-names>J.</given-names></string-name></person-group><article-title>Modeling Parkinson's disease in Drosophila: what have we learned for dominant traits?</article-title>. <source>Front. Neurol.</source><year>2018</year>; <volume>9</volume>:<fpage>228</fpage>.<pub-id pub-id-type="pmid">29686647</pub-id></mixed-citation>
    </ref>
    <ref id="B38">
      <label>38.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>von Stockum</surname><given-names>S.</given-names></string-name>, <string-name><surname>Sanchez-Martinez</surname><given-names>A.</given-names></string-name>, <string-name><surname>Corra</surname><given-names>S.</given-names></string-name>, <string-name><surname>Chakraborty</surname><given-names>J.</given-names></string-name>, <string-name><surname>Marchesan</surname><given-names>E.</given-names></string-name>, <string-name><surname>Locatello</surname><given-names>L.</given-names></string-name>, <string-name><surname>Da Re</surname><given-names>C.</given-names></string-name>, <string-name><surname>Cusumano</surname><given-names>P.</given-names></string-name>, <string-name><surname>Caicci</surname><given-names>F.</given-names></string-name>, <string-name><surname>Ferrari</surname><given-names>V.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Inhibition of the deubiquitinase USP8 corrects a Drosophila PINK1 model of mitochondria dysfunction</article-title>. <source>Life Sci. Alliance</source>. <year>2019</year>; <volume>2</volume>:<fpage>e201900392</fpage>.<pub-id pub-id-type="pmid">30988163</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
